Search Results for

A022102

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Continue Reading »

---

Search Again

• All Trial Categories Anal  (2) Bladder/Urinary Tract Cancer  (5)    Metastatic  (2)    Neoadjuvant  (2) Brain  (9)    Glioblastoma Multiforme (GBM)  (3)    Other Brain Tumors  (3) Breast  (6)    Breast Cancer Adjuvant  (2) Cancer Control/Symptom Management  (26) Carcinoid Tumors  (1) Colorectal Cancer  (7)    Metastatic  (2)    Rectal Neoadjuvant  (1) Esophageal Cancer  (1) Gall Bladder/ Biliary Tract Cancer  (1) Head/Neck Cancer  (6) Leukemia  (1)    Acute Myeloid Leukemia (AML)  (1) Liver/Hepatocellular Carcinoma  (1) Lung Cancer  (19)    Non-Small Cell Lung Cancer  (13)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (2)       2nd Line Metastatic, Stage 4 Patients with Progressive Disease  (1)       Adjuvant Treatment for Resected NSCLC  (4)    Small Cell Lung Cancer  (6)       Extensive Stage SCLC  (4) Lymphoma  (1)    Non-Hodgkin’s Lymphoma  (1) MDS  (1) Melanoma  (1) Merkel Cell Carcinoma  (1) Multiple Myeloma  (2) Ovarian  (1) Pancreatic  (5)    Metastatic Disease  (2) Prostate  (9) Renal Cell/Kidney Cancer  (3)    Locally Advanced/Metastatic  (3) Sarcoma  (2)